IL6 and COVID-19: Beyond glucose metabolism, DPP-4 functions as an immunomodulator; its inhibition reduces inflammatory cytokines (e.g., IL-6, TNF-α) and improves endothelial function, potentially mitigating severe COVID-19–related inflammation and thromboembolic risk [14,19].